Postoperative Sequence Chemoradiotherapy Compared With Chemotherapy Alone for Advanced Gastric Cancer
Status:
Unknown status
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
Gastric cancer is one of the most prevalent malignancies in China; the survival rate remains
poor despite potentially curative resections. Complete surgical resection is the only
potentially curative therapy available to patients with gastric cancer. However, even after a
complete resection with negative margins, many patients will experience recurrence. In recent
years, the radiation therapy in the carcinoma of the stomach represents a new issue that
should be addressed accompanying the development of radial physics and radial biology, the
clinical application of computed tomographic (CT) simulation and digital reconstitution
technique, especially the application of 3-dimensional conformal and intensity modulated
radiation therapy. Radiation therapy plus concurrent chemotherapy has been demonstrated to
cause a significant improvement in overall and disease-free survival according to Intergroup
Trial 0116/SWOG 9008. So the investigators designed the trial to see whether a postoperative
sequence chemoradiotherapy including oxaliplatin fluorouracil-based regimen can improve
survival for advanced gastric cancer.